Aussie council's $50,000 move prompts worried dad to scour roads for weeks
Matthew Zammit is fighting to keep the controversial mode of transportation off the streets of north Melbourne after the Darebin City Council revealed a $50,000 trial of share hire e-scooters and e-bikes would kick off in June. The decision caused waves when it was announced late last year, just a week after the City of Melbourne voted to ditch the electronic two-wheelers following a string of complaints.
At the time, Darebin's then-mayor Susanne Newton told the ABC that despite safety concerns, she believed the benefits of the trial would outweigh the risks, and that she was 'pretty comfortable' with the technology hire companies have in place.
However, Zammit disagrees, arguing residents will undoubtedly 'get hurt'. 'You hit a pothole on [an e-scooter] and all the weight is up the back, so it becomes like a lever and just catapults you forward, headfirst into whatever's in front of you,' he told 9News.
Since their introduction in Australia in 2018, e-scooters have become a hotly-contested subject due to soaring rates of serious injuries and fatal collisions, including a Perth dad who was recently hit by one as he walked to pick up dinner. He died several days later, on June 3, in hospital.
From January, 2020 to April this year, there have been 30 fatalities nationwide, with more than 10 of them being children. Staggering research from the University of Melbourne revealed that one in three e-scooter deaths in the last five years have been children, prompting a plea to parents not to buy the electric scooters for their kids.
'They end up with lots of soft tissue and facial fractures, sometimes half or all of their teeth missing, and unfortunately sometimes really significant head injuries,' Dr Sarah Whitelaw from the Royal Melbourne Hospital said.
Earlier this week, Yahoo News published heart-stopping dashcam footage of a Queensland child's very close call after she suddenly swerved in front of a car while riding an e-scooter without a helmet. Driver Emma Ogilvie said the incident left her feeling 'so shaken'.
'She's just lucky I pay attention when I drive and I saw her. It could've been a lot worse, and although it would't have been my fault, I couldn't live with myself if anything else happened,' she told Yahoo.
Zammit, a survivor of road trauma, has created a Change.org petition to urge Darebin City Council to reverse what he says is an 'expensive and harmful' decision.
'As a result of this road trauma I live with significant disabilities, including an acquired brain injury,' he wrote on the website. 'It has changed the course of my life, and I am startled by the level of brain injury being inflicted on others due to shared e-scooters.'
Speaking to 9News, Zammit said the last thing he wants is to see someone else be severely injured or killed while riding an e-scooter on his local streets. 'You see statistics of people seriously injured on roads and you can very easily just see a number, but each one of those serious injuries is a long journey of recovery,' he said.
'And in many cases, you're not going back to what you were. You're not getting back what you had... your life has changed forever.'
🚘 Dashcam captures driver's 'heart attack' e-scooter moment in front of car
🧒 Urgent plea to Aussie parents over deadly e-scooter trend
👀 Little-known road rule could see you lose your licence
Darebin's new mayor Kristin Olaris has insisted the council is 'putting safety and accessibility at the centre' of its impending trial, according to 9News.
Peter McLean, CEO of Bicycle NSW, told Yahoo there are multiple factors that contribute to e-scooter and e-bike safety, including government regulations, police enforcement and parental responsibility.
'E-scooter sales have been significantly increasing over time and tens of thousands of them are being sold each and every year across Australia,' he said. 'They do provide a significant improvement in autonomous transport and transportation, which is very, very positive. However, we do have to be very, very careful how we use them.
'If you're not riding them correctly then they are extremely dangerous and will undoubtedly injure the user and of course, other road users as well.'
Do you have a story tip? Email: newsroomau@yahoonews.com.
You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Novel Peptides Expressed in HIV Could Drive Treatment
Genetic sequencing of peptides in rebound virus in individuals with HIV who had analytic treatment interruptions (ATIs) confirmed the peptides' expression in HIV-1 infection, according to data presented at the International AIDS Society Conference on HIV Science. Previous research has shown that HIV-specific CD8 T-cell responses directed against five genetically conserved HIV-1 protein regions (Gag, Pol, Vif, Vpr, and Env) are associated with viral control, wrote Josefina Marín-Rojas, PhD, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, and colleagues in their abstract. However, data on whether these peptides are expressed in rebound virus among individuals with HIV who experienced ATI are limited, they wrote. The researchers applied an immunoinformatics analysis pipeline (IMAP) to select 182 peptides (IMAP-peptides) from structurally important and mutation-intolerant regions of HIV-1 proteins, said senior author Sarah Palmer, PhD, co-director of the Centre for Virus Research at the Westmead Institute for Medical Research and professor in the Faculty of Medicine and Health at the University of Sydney, in an interview. 'Our studies indicate if the immune system targets these structurally important and mutation-intolerant regions of HIV-1 proteins, this can contribute to virological control in the absence of HIV-1 therapy,' she explained. The researchers reviewed data from the PULSE clinical trial, which included 68 men who have sex with men living with HIV in Australia. The study participants underwent three consecutive ATIs. A total of seven participants' transiently controlled HIV rebound during the third ATI. The researchers examined whether the IMAP peptides were present in the HIV-1 RNA sequences of the rebound virus in four noncontrollers (patients who had viral rebound in all three ATIs) and five of the seven transient controllers who showed viral control during the third ATI. The technique of near full-length HIV-1 RNA sequencing of rebound virus from three noncontrollers and two transient controllers identified the Gag, Pol, Vif, Vpr, and Env IMAP-peptides in 52%-100% of the viral sequences obtained from these participants across three ATI timepoints. 'We assumed that cells from people living with HIV that experience virological control after treatment interruption would have the immune response to our IMAP-peptides that we observed; however, we are amazed and encouraged by the level and extent of this immune response,' Palmer told Medscape Medical News . The researchers also compared CD8 T-cell response between the IMAP peptides and a control peptide pool without the IMAP peptides. The CD8 T-cells from three transient controllers had a 15- to 53-fold higher effector response to the IMAP-peptides than the CD8 T-cells from two noncontrollers, the researchers wrote in their abstract. The relative response to the IMAP-peptides in noncontrollers was 20 times lower than that to the control peptides, but the IMAP-peptide response in transient controllers group was similar to that in the control group, the authors noted. The results highlight the potential of IMAP in developing treatment strategies. Although the results are too preliminary to impact clinical practice at this time, the findings from the current study could lead to the development of an mRNA vaccine to clear HIV-infected cells from people living with HIV, Palmer told Medscape Medical News . 'Our next steps include developing and testing mRNA vaccine constructs that contain our IMAP-peptides to assess the immune response of cells from people living with HIV to these vaccines,' Palmer told Medscape Medical News . 'From there we will conduct studies of the most promising mRNA vaccine constructs in a humanized mouse model,' she said. Data Enhance Understanding of Immunity The current study may provide information that can significantly impact understanding of the immune responses to HIV, said David J. Cennimo, MD, associate professor of medicine & pediatrics in the Division of Infectious Disease at Rutgers New Jersey Medical School, Newark, New Jersey, in an interview. 'The investigators looked at highly conserved regions of multiple HIV proteins,' said Cennimo, who was not involved in the study. 'Conserved regions and antibody responses to them may play a role in controlling HIV viral replication and rebound,' Cennimo told Medscape Medical News . 'The investigators showed these regions were present in rebounding viremia, and individuals that exhibited greater immune recognition of these regions suppressed rebound viremia longer, and perhaps targeting these regions could impact HIV prevention or cure strategies,' he said. Secondarily, the study showed the success of the novel technique (IMAP) to identify conserved peptides, said Cennimo. The technique could potentially be applied to other viruses that mutate to escape host response, he said. The study was funded by the US National Institutes of Health, the Foundation for AIDS Research, the Australian National Health and Medical Research Council, and Sandra and David Ansley. The researchers disclosed no financial conflicts of interest.
Yahoo
5 hours ago
- Yahoo
Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high production costs and geographic logistics, ongoing research and community engagement aim to enhance antivenom efficacy and accessibility. Major companies include CSL Limited and Pfizer Inc. Australian Anti-Venom Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Anti-Venom Market - Healthcare Demand & Forecast 2025-2033" report has been added to Anti Venom Market is expected to reach US$ 39.27 million by 2033 from US$ 22.18 million in 2024, with a CAGR of 6.55% from 2025 to 2033. Increasing rates of snake bites and scorpion stings, the introduction of beneficial government programs, and continuous industry advancements are some of the major factors propelling the market's expansion. The anti-venom business in Australia is essential to safeguarding the general public's health from the deadly and varied animals of the nation. The need for efficient anti-venom therapies is constantly high in areas with a high population of poisonous snakes and spiders. The industry functions through a network of organizations in charge of producing anti-venom, conducting research, and extracting venom. Together, these groups strive to guarantee a consistent flow of therapies that can save lives throughout the order to create anti-venom, venom from animals is usually collected and used to immunize host animals, such horses. The anti-venom is then made by harvesting and purifying antibodies. Although this approach hasn't altered much in decades, it still works well. The sector still confronts obstacles despite its shown success, such as high production costs and the requirement for anti-venoms that are appropriate for certain venom kinds. To overcome these obstacles and enhance results, research and innovation are still being conducted. Researchers are looking at universal anti-venoms that can cure various venom kinds as well as more effective manufacturing methods. Additionally, efforts are being made to make treatments more widely available, particularly in rural and isolated locations where bites are more common. In order to maintain national safety as the business develops, its capacity to address public health demands continues to be a top Factors Driving the Australia Anti Venom Market Growth High Incidence of Venomous BitesSome of the deadliest snakes and spiders in the world, such as the eastern brown snake, funnel-web spider, and inland taipan, may be found in Australia. A steady number of envenomation cases occur annually as a result of the widespread presence of these harmful species across the nation. The ongoing need for efficient anti-venom remedies is fueled by this public health concern. Particularly in rural and isolated areas where interactions are more frequent, hospitals and emergency services need to keep enough supplies on hand to react promptly to bites. Continued investment in the development and dissemination of anti-venoms is guaranteed by the necessity to treat both common and uncommon venom exposures. The need for dependable, quick-acting medical treatments like anti-venom therapy is growing as people become more aware of the dangers posed by local in Research and DevelopmentThe Australian anti-venom business is expanding due in large part to ongoing research and innovation. The goal of scientific research is to improve the accessibility, efficacy, and safety of therapies. The search for universal anti-venoms that can cure bites from many species is a significant area of development that might expedite emergency response and lower expenses. In order to boost productivity and lessen dependency on conventional animal-based vaccination, researchers are also trying to improve production techniques through the use of cutting-edge biotechnology. Collaboration among government organizations, pharmaceutical businesses, and academic institutions facilitates the creation of regionally customized solutions that are suited to Australia's distinct ecology. These developments guarantee that anti-venoms will continue to effectively combat changing venom characteristics and effectively and safely address public health Engagement and Public AwarenessIn Australia, the anti-venom business is greatly aided by community engagement. To properly catch and milk poisonous creatures, programs like wildlife parks' venom collecting campaigns need on volunteers and skilled specialists. In order to create medicines that can save lives, this gathered venom is essential. Public education initiatives also assist lower the number of fatalities and problems by increasing knowledge about the safety of snakes and spiders, first aid procedures, and the value of prompt medical attention. Raising awareness also promotes public and private funding for the study and manufacture of anti-venom. Australia guarantees a more proactive and robust approach to addressing the hazards posed by venomous animals by cultivating a culture of shared responsibility among scientists, healthcare professionals, and the general in the Australia Anti Venom Market High Production CostsThe high cost of manufacture is one of the main issues facing the Australian anti-venom business. The production of anti-venoms usually entails a time-consuming procedure that includes venom vaccination of animals (like horses) followed by the collection and purification of the antibodies. Manufacturing costs are increased by this labor-intensive and intricate process, which calls for specialized facilities and knowledgeable workers. Additionally, keeping a steady supply of venom from a variety of species raises the operational and logistical expenses. These costs can restrict access and frequently result in significant costs for healthcare providers, especially in rural or resource-poor locations where envenomation cases are more and Logistical ChallengesThe dissemination of anti-venoms is severely hampered by Australia's large and sometimes rural terrain. A large number of envenomation cases take place in isolated and rural areas with little access to healthcare services. It can be challenging to get temperature-sensitive anti-venoms to these locations in a timely and reliable manner, particularly in the event of severe weather or infrastructural failures. Coordinated logistics and significant money are needed to guarantee that remote clinics and hospitals have enough inventory. In these areas, inadequate access might cause treatment delays and worsen health outcomes. Improving response times and guaranteeing that all Australians, wherever they may be, have access to life-saving anti-venoms depend on resolving these logistical concerns. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Bharat Serums and Vaccines Limited (BSV) Boehringer Ingelheim International GmbH Boston Scientific Corporation CSL Limited. Merck KGaA Pfizer Inc. Haffkine Bio-Pharmaceutical Corporation Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $22.18 Million Forecasted Market Value (USD) by 2033 $39.27 Million Compound Annual Growth Rate 6.5% Regions Covered Australia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Australia Anti Venom Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Type6.2 By Animal Type6.3 By End Users7. Type7.1 Polyvalent Anti-Venom7.2 Monovalent Anti-Venom8. Animal Type8.1 Snake8.2 Scorpion8.3 Spider8.4 Others9. End Users9.1 Clinics9.2 Hospitals9.3 Ambulatory Surgical Centers9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Anti-Venom Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
6 hours ago
- Fox News
Doctor reveals the secret weapon against growing vaccine skepticism worldwide
Although it's been more than five years since the start of the COVID-19 pandemic, the resulting vaccine hesitancy still lingers to this day — something Professor Margie Danchin is committed to helping solve. A pediatrician at the Royal Children's Hospital in Melbourne, Australia, Danchin is also a vaccine expert at the Murdoch Children's Research Institute (MCRI), also in Melbourne. Her biggest focus, she told Fox News Digital, is fighting the erosion of vaccine confidence at a time when technology is advancing — and when the need for these advances to fight emerging (and re-emerging) childhood diseases is growing. One prime example of this technology, according to Danchin, is the new maternal vaccination against RSV (respiratory syncytial virus) and the RSV monoclonal antibody treatment for newborns, called nirsevimab. These are new and effective weapons against an illness that is a leading global cause of infant pneumonia and hospitalization of newborns. In Western Australia and Queensland, Danchin said, nirsevimab has led to an 80% decrease in hospitalizations from RSV. Fox News Digital spoke to Danchin about this paradox between exciting new tools of prevention and the reluctance to use them. In Australia, childhood vaccination rates are falling in many areas, mirroring other regions in the U.S. and around the world. "We have the lowest levels of trust in all vaccines in more than a decade — and in effect, we've had global reductions in vaccine coverage for children in particular," Danchin said. She also pointed to the escalation of vaccine-preventable diseases, such as diphtheria, polio, whooping cough and measles. Professor Danchin's research focuses on vaccine hesitancy and what to do about it. "It needs to be tackled on many levels," she said. Some of the biggest factors, according to the doctor, are people's worldviews, perceptions and understanding of risk, as well as the cognitive biases they use to interpret that risk. "We saw through the COVID rollout, when there were adverse events associated with vaccines, people became incredibly fearful that was going to happen to them — even though the actual risk of that occurring was incredibly low, very rare," Danchin said. The doctor aims to address patients' concerns while at the same time building trust. One strategy is the Vaccine Champions Program, which has been rolled out in Australia as well as five countries in the Asia-Pacific region. "We build capacity and train healthcare providers and diverse community leaders — including religious leaders, teachers and sporting stars — on how to communicate about vaccines," Danchin said. Storytelling narratives can also be an effective way to convey the importance of vaccines, the doctor noted. She said she strives to establish herself as "somebody with knowledge and expertise and credibility," while at the same time being respectful and ensuring that parents feel their concerns are heard. "I build rapport, and then I spend time actually addressing those concerns and sharing trustworthy information," Danchin said. She also takes the time to discuss the diseases themselves, she said. "I think we spend too much time focusing on the vaccines, which have become a victim of their own success," Danchin said. "Parents forget why we're vaccinating and what the diseases we're trying to prevent could do to their children." Above all, Danchin said, it's important for people to have access to trustworthy sources of information rather than existing in "echo chambers," where they read and share information that may not be accurate or well-sourced. "We need trusted scientists who can actually communicate," Danchin said. Danchin emphasized that most people are not unintelligent about this topic — "they're just very confused. They don't know what to believe." It's important to be respectful of others' views and to "invite open conversation," the doctor said. "If you censor information, then people become distrusting," she cautioned, noting that conversations must be held "with clarity, without aggression or judgment." Danchin also said she strives to dispel the lingering concerns among some parents about the possible link between certain vaccines and autism. To accomplish that, she listens to parents' concerns and then "gently shares" the 25 years of research that disprove that association, she said. "I think we spend too much time focusing on the vaccines, which have become a victim of their own success." "Just because you have a vaccine, and then in the next four to six months, your child's communication skills and behavior changes, doesn't mean that X caused Y," Danchin said. "If you have a banana and then you have a reaction, it doesn't mean the reaction is from eating the banana." During the pandemic, Danchin noted, there were many instances where people felt that if an elderly person had a COVID vaccine and then died a week later, it was clearly the vaccine that caused the death, even though it could have been due to a stroke or heart attack. "So that's what I do with families — I gently explain the research. I show them that there's absolutely no evidence," she said. "There have been millions of children who have not received the MMR vaccine and others who have received it, and there's been no difference in the incidence of autism." For more Health articles, visit Danchin aims to approach parents "with clarity, without aggression, without judgment, and by using a ground-up approach." At the same time, the doctor said she and her fellow researchers "are constantly monitoring for vaccine side effects (or vaccine safety concerns) in the community." Visit to donate or to learn more about MCRI's important research.
